How long would you continue trastuzumab and pertuzumab in a patient with ER+ HER2+ breast cancer with initially osseous involvement treated with ACT-HP and is now in CR by PET for >2 years?
Answer from: Medical Oncologist at Community Practice
All physicians who treat metastatic HER2 breast cancer eventually have patients who appear to have been "cured" of their metastatic disease with available agents. This question crops up from time to time, wondering if there is some measure of time or test we can use to determine when it would be rea...
Comments
Medical Oncologist at Arizona Hem/Onc I would consider taking advantage of NGS and circu...
Medical Oncologist at VanDeusen Oncology Consulting A very interesting point! My only concern is that ...
Medical Oncologist at NYU Winthrop Hospital Circulating tumor DNA not endorsed by NCCN in brea...
I would consider taking advantage of NGS and circu...
A very interesting point! My only concern is that ...
Circulating tumor DNA not endorsed by NCCN in brea...